Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.
Florida-based e5 said the refunds are due to recalculations of 340B ceiling prices. The company said it will pay entities by check, including payment details, sent to entities. “e5 Pharma invites interested parties to contact the company by email … with reference to the applicable NDCs,” the notice says. It includes two email addresses and one phone number for inquiries.
